AbbVie, a pharmaceutical company, is buying Aliada Therapeutics for $1.4 billion. This purchase includes Aliada’s main experimental drug, ALIA-1758, which is being developed to treat Alzheimer’s disease.
Aliada is known for its innovative technology that helps deliver drugs to the brain by crossing the blood-brain barrier (BBB). This technology is part of their MODEL platform, which was originally created by Johnson & Johnson. ALIA-1758 uses this technology to carry a specific antibody into the brain to target and break down amyloid beta plaques, which are linked to Alzheimer’s.
The acquisition is expected to enhance AbbVie’s research capabilities, helping them create new treatments for brain-related disorders. ALIA-1758 is currently in early clinical trials to test its safety. The deal is expected to be completed by late 2024, pending regulatory approval.
AbbVie aims to expand its focus on neuroscience, with the intention of addressing unmet patient needs in serious neurological diseases like Alzheimer’s.